Anaplastic large cell lymphoma medical therapy

Anaplastic large cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Anaplastic large cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Anaplastic large cell lymphoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Anaplastic large cell lymphoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Anaplastic large cell lymphoma medical therapy
CDC on Anaplastic large cell lymphoma medical therapy
Anaplastic large cell lymphoma medical therapy in the news
Blogs on Anaplastic large cell lymphoma medical therapy
Directions to Hospitals Treating Anaplastic large cell lymphoma
Risk calculators and risk factors for Anaplastic large cell lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

• Managed under "Aggressive Lymphoma" guidelines
  • CHOP is first line of treatment, CHOP-Rituxan in the unlikely scenario that CD20 is positive, given that CD20 is a B-cell marker.
  • Radiation therapy as per institutional preference (based on ECOG, SWOG, and GELA trials), but usually added for bulky disease
• Overall better prognosis than other "Aggressive Lymphomas"
  • ALK+ 5-year survival 70-80%
  • ALK- 5-year survival 30-40%